Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Augmentation in Treatment-Resistant Depression
NCT00044681Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2002
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in treatment-resistant depression (TRD), sponsored by Johnson & Johnson. Started Oct 2002; status: completed.
02
Drugs
risperidone
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT00044681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044681.